November 5th, 2019
Results from the phase 1-2 clinical trial assessing the benefits of UM171-expanded cord blood transplantation for the treatment of hematological diseases are published in Lancet Hematology.
Ici Radio-Canada – Espoir québécois dans la lutte contre le cancer du sang
La Presse – Une greffe prometteuse pour les gens atteints de cancers du sang
Montreal Gazette – New leukemia treatment promises astounding results, few side-effects
La Presse – Personnalité de la semaine : Guy Sauvageau
October 24-26, 2019
The Leucegene team attended the ESH AML conference in Estoril, Portugal.
clic here for Guy Sauvageau’s interview on “why should we target RUNX1 in AML treatment”
May 3rd, 2018
Guy Sauvageau, Josée Hébert and the Leucegene team are awarded $12.8 million in funding from Genome Canada and Genome Quebec to continue their work on AML. Click here for more information.